Chicago, United States
VectorBuilder, founded in 2014, has emerged as a global leader in the biotechnology industry, specializing in gene delivery technologies. The company's influence is substantial, serving over 50,000 customers from research institutions, universities, and biotech/pharma companies worldwide. Its expansive reach is evident from its operational presence spanning North America, Europe, China, Japan, South Korea, and Australia.
Offering a comprehensive range of solutions from research to clinical applications, VectorBuilder is recognized for its innovation and affordability. Its commitment to high-quality service is reinforced by a dedicated PhD-level support team, resulting in strong customer satisfaction and critical acclaim in prestigious publications.
The company recently attracted investor attention with a venture round investment on May 23, 2023, propelling it further towards its mission of advancing gene delivery technologies. VectorBuilder positions itself as a key player in the future of gene delivery, promising significant opportunities for potential investors.
